PTSD (Posttraumatic Stress Disorder) is a serious condition often caused by traumatic experiences. Some patients don't fully benefit from existing treatments. This study explores a new approach using a drug called MDMA (3,4-methylenedioxymethamphetamine) combined with Prolonged Exposure therapy (PE), a well-established PTSD treatment. MDMA can enhance feelings of closeness and empathy, potentially making therapy more effective. Participants will receive MDMA during a 10-day therapy program at the Emory Brain Health Center. Researchers will collect data to see if MDMA improves PE therapy for PTSD.

• Study duration: 10 days with daily therapy sessions.
• MDMA given only on the second day of treatment.
• Participants will have follow-up assessments at 1, 2, and 4 weeks post-treatment.

This study seeks individuals with PTSD who are medically suitable for MDMA. Participants must be able to understand English, provide informed consent, and agree to lifestyle changes during the study.